Enabling 21st Century scientific innovation BenevolentAI is the world leader in the development and application of artificial intelligence for scientific innovation. We are the largest private AI company in Europe and one of the top five private AI companies in the world.
Changing the way discovery happens Despite the explosive growth of data, scientific discovery has not changed for 50 years. It is impossible for humans alone to process all the world’s available scientific data and literature. Consequently, only a tiny fraction of scientific knowledge is accessible, decipherable and usable at any one point in time to a given scientist.
Augmenting human intelligence BenevolentAI uses proprietary AI and machine learning technology, together with its own unique team of pioneering scientists, to look deeply into vast scientific research data sets - rapidly forming and qualifying hypotheses, generating new insights and enabling hitherto impossible scientific intuition and innovation at previously unimaginable scale.
Discovering new medicines We began with a focus on bioscience – increasing the understanding of human biology by ingesting the entire compendium of information on human health and biological systems. We are applying this knowledge to pharmaceutical development to bring better medicines to patients faster.
May 25, 2017 news - announcements AI enabled research shows delay in onset of motor neurone disease Sheffield and London, UK - 25 May 2017. The Sheffield Institute for Translational Neuroscience (SITraN), part of the University of Sheffield and one of the world’s leading centres for research into Motor Neurone Disease, Alzheimer’s and Parkinson’s Disease, today announced that its research into a drug candidate discovered by British artificial intelligence firm BenevolentAI has delivered positive results. ARTIFICIAL INTELLIGENCE , DRUG DISCOVERY View news
Apr 11, 2017 news - announcements BenevolentAI agrees partnership with medical research charity MRC technology London, 11 April 2017 – BenevolentAI, a British artificial intelligence company, today announced that it has partnered with MRC Technology (“MRCT”), a medical research charity, to explore drug discovery initiatives in the field of small molecules and antibodies. DRUG DISCOVERY , SCIENCE , BIOMEDICAL , ARTIFICIAL INTELLIGENCE , BENEVOLENTAI View news
Feb 21, 2017 news - articles Bold claims for AI are hard to compute for economists The Financial Times takes a look at the work we’re doing at BenevolentAI to “revolutionise medical research” after speaking to Co-Founder and Director, Ken Mulvany. ARTIFICIAL INTELLIGENCE , TECH , BUSINESS , KEN MULVANY , DISRUPTIVE , TRENDS , BENEVOLENTAI View news
Jan 6, 2017 news - articles BenevolentAI gets The Economist thinking on biology and AI We met with The Economist to discuss how artificial intelligence (AI) and machine learning is helping to crack and transform the scientific method. ARTIFICIAL INTELLIGENCE , DRUG DISCOVERY , SCIENCE , NATURAL LANGUAGE PROCESSING , MACHINE LEARNING , BIOLOGY View news
